• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Innocan Pharma Corp (OP: INNPF )

    0.1055 UNCHANGED
    Last Price Updated: 9:30 AM EDT, Oct 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.1055
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.1055
    Today's Range 0.1055 - 0.1055
    52wk Range 0.0908 - 0.3000
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
    Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance. 
    Via Benzinga
    This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
    Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -56.60%
    -56.60%
    1 Month
    N/A
    N/A
    3 Month
    -44.47%
    -44.47%
    6 Month
    -49.55%
    -49.55%
    1 Year
    -53.42%
    -53.42%

    More News

    Read More
    534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
    Via Benzinga
    CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
    Via Benzinga
    Exposures Product Safety
    4 CBD Stocks in the Canadian Capital Market
    Via Benzinga
    Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis Product Safety
    CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
    Via Benzinga
    Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
    Via Benzinga
    Cannabis Stock Gainers And Losers From August 25, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Innocan Pharma Secures $1.4M Via Private Placement
    Via Benzinga
    Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Innocan Pharma To Secure Up To $3M Via Private Placement Of Units At A 9% Prime Above Share Price
    Via Benzinga
    Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Cannabis Stock Movers For July 21, 2023
    Via Benzinga
    Cannabis Stock Gainers And Losers From August 14, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Innocan Pharma Q1 Revenue Grows 500%, Here Is What You Need To Know
    Via Benzinga
    Cannabis Stock Gainers And Losers From August 11, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Innocan Pharma FY22 Revenue Grows 1205% To $2.6M, Here Is What You Need To Know
    Via Benzinga
    Can Liposomal CBD Injection Help Dogs With Polyarthritis? Innocan Pharma Reports Clinical Success
    Via Benzinga
    Innocan Pharma Q3 Revenue Grows 700% YoY, Here Is What You Need To Know
    Via Benzinga
    Innocan Pharma Provides an Operational Update
    Via Newsfile
    Topics Intellectual Property
    Exposures Intellectual Property
    Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
    Via Newsfile
    Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
    Via Newsfile
    Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
    Via Newsfile
    Topics Intellectual Property Supply Chain
    Exposures COVID-19 Intellectual Property Supply Chain
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.